Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Verinata Health has received the US Patent No 8,008,018 for its fetal aneuploidy determination method from the US Patent and Trademark Office (USPTO).
Subscribe to our email newsletter
The new patent covers methods for determining the presence or absence of a fetal aneuploidy, or an abnormal number of fetal chromosomes, by analysis of blood samples from pregnant women.
Verinata Health CEO Caren Mason said that they are pleased that the USPTO has recognized this invention from Quake laboratory at Stanford that provides foundation for their prenatal diagnostic test.